Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT05745610

Shen Hai Long Capsule for Male Asthenospermia

Conditions: Efficacy and Safety of Shen Hai Long Capsule for Mild to Moderate Asthenospermia in Men

Sex: Male
Ages: 22 Years – 50 Years
Phase: NA
Enrollment: 120
Sponsor: Zhongnan Hospital

Location: China

Summary

To evaluate the efficacy and safety of Shen Hai Long Capsule in the treatment of mild to moderate asthenospermia in men.

Eligibility Criteria

Inclusion Criteria:Age range from 22 to 50 years old;Patients with mild to moderate asthenospermia, that is, at least two normative semen analyses indicated that 10%≤PR percentage < 32% and the total number of PR sperm ranged from 5 million to 20 million;At least two standard semen analyses indicated that sperm concentration ≥15×106 /ml; Sperm normal morphology rate ≥4%;No other Chinese and Western drugs for the treatment of oligospermia, weak and malformed spermia have been taken in the past 3 months;The subject voluntarily participates and signs the informed consent.Exclusion Criteria:Varicocele, ejaculatory duct/seminal vesicle cyst, anti-sperm antibody (+);Genital tract infection: seminal plasmic elastase > 1000ng/ml or leukocyte semen disease (peroxidase positive cell concentration in semen more than 1×10^6/mL);Erectile dysfunction, ejaculation disorders;suffer from mental disorders, immune system diseases; Severe impairment of liver and kidney function (serum transaminase ≥2× upper limit of medical reference value, creatinine clearance ≤40ml/min or active stage of chronic kidney disease);Patients with allergic history or constitution to therapeutic drugs;Patients who have taken drugs affecting the study within 3 months, such as antitumor and antiepileptic drugs, etc.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05745610). StuddyBuddy aggregates publicly available trial information.